GlycoOptimized Follicle-Stimulating Hormone FSH-GEX (GT-GP 2.4-GEX)

The Follicle Stimulating Hormone (FSH) is responsible for follicle maturation. Its main clinical use is administration during the onset of in vitro fertilization procedures to induce maturation of multiple oocytes for retrieval.

Clinical use for FSH is mainly in the treatment of unovulatory infertility. Currently approved preparations of FSH stem from either urinary or recombinant sources. While urinary versions of FSH do come at somewhat lower costs, the in general better safety of recombinant products makes them the product of choice for most patients, despite higher costs associated with the treatment.

Glycotope’s glycooptimized version of FSH, FSH-GEX combines the advantages of both product types into one single product. With an improved half-life and superior production yields, FSH-GEX provides the safety advantages of a recombinant protein and a fully human host cell line with the economic benefits of urinary preparations.

FSH-GEX will enter clinical phase I in Q2 /2011.